Glutamine does not prevent paclitaxel-associated myalgias and arthralgias.

摘要: Myalgias and arthralgias are prominent toxicities associated with paclitaxel. Pursuant to pilot information suggesting that glutamine could markedly alleviate this toxicity, we developed a placebo-controlled, double-blind, randomized crossover trial test hypothesis. This studied 36 patients who had experienced myalgias/arthralgias related prior paclitaxel-containing regimen were then receive oral (10 grams three times day, starting on the day of chemotherapy) x 5 days or an identical-appearing placebo. For subsequent cycle chemotherapy, crossed over, again in double-blind manner, alternative treatment. Patients recorded daily myalgia/arthralgia scores numerical scales. Physicians patient-reported using National Cancer Institute common toxicity criteria at baseline after each course therapy. The results study revealed no effect development severity paclitaxel-induced myalgias/arthralgias, as either by patients' logs physician-reported information. Glutamine was well tolerated, suggestion more compared Upon completion two cycles, asked indicate which blinded courses they preferred. Of those indicating preference, 29% preferred cycle, 33% placebo (P = 0.96). Thus did not suggest any role for glutamine, placebo, preventing development, alleviating severity, myalgias/arthralgias.